{"id":"W3123515346","doi":"10.1200/jco.2021.39.3_suppl.82","title":"Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Regorafenib; Atezolizumab; Oncology; Internal medicine; Colorectal cancer; Irinotecan; Oxaliplatin; Clinical endpoint; Phases of clinical research; Cancer; Clinical trial; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003373092,0.002527674,0.002248784,0.0005257116,0.0004221536,0.001392788,0.0011403,0.001796996,0.007956471],"category_scores_gemma":[0.00206668,0.0009590901,0.001710123,0.0004544645,0.001442572,0.001541477,0.000584179,0.003745088,0.001402184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001383711,"about_ca_system_score_gemma":0.001763693,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008598042,"about_ca_topic_score_gemma":0.002461978,"domain_scores_codex":[0.9990876,0.0005395887,0.00004750439,0.0001332157,0.0000552385,0.0001368443],"domain_scores_gemma":[0.9986113,0.0002712333,0.0003998458,0.0001017844,0.00007925547,0.0005364312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9611234,0.01743162,0.0006964798,0.0003794506,0.0004388629,0.00003962078,0.00005252992,0.0005792598,0.00474763,0.0001227344,0.0009299127,0.01345848],"study_design_scores_gemma":[0.8457602,0.1509694,0.001062636,0.00001907236,0.0002228861,0.00004326844,0.00002434525,0.0005113839,0.0005701897,0.0001388237,0.0006670521,0.00001073867],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791585,0.002689175,0.001147473,0.0009723147,0.0004829534,0.01079987,0.001883683,0.0001926431,0.002673496],"genre_scores_gemma":[0.9786928,0.001723487,0.002414274,0.001440767,0.0004819059,0.009398725,0.001873702,0.00004633937,0.003928062],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007956471,"threshold_uncertainty_score":0.02661705,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2516595996139932,"score_gpt":0.548639827681197,"score_spread":0.2969802280672038,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}